We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Report Predicts Double-Digit Growth for Protein Microarrays

By LabMedica International staff writers
Posted on 19 Jan 2015
Microarrays are in great demand for studying the workings of proteins, to discover new biomarkers and even new drugs, and for diagnostics. More...
Among the tests useful in protein analysis, microarrays were among the fastest revenue growth category, according to Kalorama Information’s (New York, NY, USA) latest report “Proteomics Markets Research and IVD Applications.”

Protein microarrays are arrays of proteins or peptides immobilized onto a solid surface such as a glass slide, membrane, microtiter plate, or other solid surface. The market for proteomics instruments, reagents, and testing topped USD 5 billion in 2013. Also according to the report, while the entire market will grow at high single-digits, the microarray market within proteomics will grow at 15% revenue growth per year for the next 5 years.

“The proteomics market is expected to continue to grow as researchers continue to work on basic understanding of the human proteome, and as researchers apply these discoveries in fields such as biomarker discovery and validation, drug discovery and development, diagnostics, and personalized medicine,” said Bruce Carlson, publisher of Kalorama Information.

The report identifies three main types of protein microarrays. Analytical microarrays: Analytical protein (or antibody) microarrays use immobilized antibodies to detect proteins in biological samples, often via use of a secondary antibody in principle similar to a sandwich immunoassay. Functional microarrays: With functional protein microarrays purified recombinant proteins are immobilized onto the solid phase. These microarrays can then be used to study enzymatic activity or to identify protein-protein (or peptide), protein-DNA, protein-RNA, protein-phospholipid, protein-drug, or other interactions with the immobilized proteins. They can also be used to detect antibodies in a biological specimen to profile an immune response. Protein lysate microarrays (also called reverse-phase protein microarrays): Complex samples such as lysates from tissues or cells are arrayed onto the solid phase, and then probed with antibodies to a target protein of interest.

Companies have used microarray principles, combined with their own proprietary technologies, to develop a wide range of protein microarrays. Kalorama Information's report features more than 20 firms involved in development and marketing of protein microarrays, detailing products and expected earnings for companies involved in microarrays and other proteomics. The report contains breakouts of the market by type of technology used and application. It profiles companies and surveys partnerships and deals related to proteomics.

Related Links:

Kalorama Information
Proteomics Markets for Research and IVD Applications, report



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Automated Urinalysis Solution
UN-9000
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.